

\$SITENAME - (\$SITECODE)

▲ \$USERNAME

Concomitant Medication (CM1)

Web Version: 1.0; 1.00; 08Dec20

Segment (PROTSEG):/	4
CM Number (CMSPID):	

Only enter medications on this form taken on the day of enrollment. NOTE: Hydroxyurea treatment taken within 30 days of enrollment is an exclusion	criterion for this study.
Medication:(CM1TRT)	
Start date:(CM1STDT)	
Indication:(CM1INDC) Stop date:(CM1ENDT)	0-Exact date 3-Day only unknown 2-Day and month unknown (ddMMMyyyy) (CM1STEST) 1-Day, month, and year unknown
	(ddMMMyyyy) (CM1ENEST)
	(CM1ONGO) [□] 9-Ongoing

Additional Selection Options for CM1

CM Number (CMSPID) (key field):

001-1 002-2

003-3

004-4

005-5 006-6

007-7

8-800

009-9

010-10

011-11

012-12

013-13 014-14

015-15

016-16 017-17

018-18

019-19

020-20 021-21

022-22

023-23

024-24

025-25

026-26

027-27 028-28

029-29

030-30 031-31

032-32

033-33

034-34

035-35 036-36

037-37 038-38

039-39

040-40

041-41

042-42 043-43

044-44

045-45 046-46

047-47

048-48 049-49 050-50



\$SITENAME - (\$SITECODE)

▲ \$USERNAME

Demographics (DEM)

Web Version: 1.0; 1.00; 08Dec20

Gender:(GENDER) Date of birth:(BIRTHDT)	M-Male F-Female (ddMMMyyyy)	
Ethnicity:(ETHNIC)	1-Hispanic or Latino 2-Not Hispanic or Latino 3-Not reported 4-Unknown	
American Indian or Alaskan Native:(AMERIND) Asian:(ASIAN) Native Hawaiian or other Pacific Islander:(PACIFIC) Black or African American:(BLACK)	1-Refused N-No Y-Yes N-No Y-Yes N-No Y-Yes N-No Y-Yes N-No Y-Yes N-No Y-Yes	
Race:(RACE)		_
	00-UNKNOWN 99-MULTIPLE 01-AMERICAN INDIAN OR ALASKA NATIVE 02-ASIAN 03-NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER *Additional Options Listed Below	~

Additional Selection Options for DEM

Race: 04-BLACK 05-WHITE



\$SITENAME - (\$SITECODE)

▲ \$USERNAME

Participant: (PATID)			(xxx-xxx-xxx)
Enrollment date:(STARTDT)		(de	dMMMyyyy)
Inclusion Criteria		,	••••
All answers in this section must be YES for the participant to be eligible. The Not a which criteria were not assessed (i.e., evaluation discontinued once participant wa 1.Diagnosis of sickle cell disease with genotype HbSS, HbS/ β^0 Thalassemia, HbSD,	s identified	d as ineligibl	(e)
or HbSO.(V101INC) 2.Age 18-45 years (35-45 year-old patients must be followed at BCH).(V102INC)	N-No	_	A-Not assessed
 Receiving regularly-scheduled blood transfusions or exchange transfusions as part of existing medical care. (V103INC) 			A-Not assessed
4.Adequate hematologic parameters including: a. White blood cell (WBC) count within the range of 2.5 - 25.0 x 10 ⁹ /L	□ N-No	Y-Yes	A-Not assessed
b. Hemoglobin within the range of 7 - 11 g/dL			
c. Platelet count within the range of 150 - 700 x $10^9/L$			
(V104INC) 5.Adequate organ function and performance status:	N-No	Y-Yes	□ A-Not assessed
a. Karnofsky performance status ≥70%			
 Serum creatinine <!--=1.5 times the upper limit of normal for age, and<br-->calculated creatinine clearence or GFR >/=60 mL/min/1.73m². 			
(V105INC) 6.Adequate venous access or an existing venous access device.(V106INC) Exclusion Criteria	□ N-No	Y-Yes	A-Not assessed
All answers in this section must be NO for the participant to be eligible. The Not as which criteria were not assessed (i.e., evaluation discontinued once participant wa 1.Participants who have uncontrolled illness including, but not limited to: a. Ongoing or active infection.	as identified	d as ineligibi	
b. Emergency room admission or hospitalization for SCD-related reason in the past 30 days.	1		
c. Major surgery in the past 30 days.			
d. Medical/psychiatric illness/social situations that would limit compliance with study requirements as determined by the treating physician.			
(V101EXC)			
 Known myelodysplasia of the bone marrow or abnormal bone marrow cytogenetics. (V102EXC) 	N-No	Y-Yes	A-Not assessed
 Receipt of an investigational study drug or procedure within 90 days of study enrollment. (V103EXC) Pregnant or breastfeeding. (V104EXC) 			A-Not assessed
,			A-Not assessed
5.Known acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on prior biopsy.(V105EXC) 6.Known left ventricular ejection fraction <40%.(V106EXC)	N-No		A-Not assessed A-Not assessed
(V107EXC)	N-No		A-Not assessed
8.ALT or AST > 2.5 X upper limit of normal or direct bilirubin > 2.0 mg/dL.($V108EXC$)) N-No	Y-Yes	A-Not assessed
9.On hydroxyurea treatment.(V109EXC)	N-No		A-Not assessed
10.Requires placement of central line for apheresis.(V110EXC)	□ N-No	Y-Yes	A-Not assessed

MAN01A (ENR)

Web Version: 1.0; 1.00; 08Dec20



■\$SITENAME - (\$SITECODE)

♣ \$USERNAME

Laboratory Results (LAB)

Segment (PROTSEG):A Visit Number (VISNO):

Baseline	Visit	Assessm	ents

Baseline collection date:(LABBASDT)

Were Baseline assessments performed?(LABBASYN)

If No, reason not done: (LABBASNO)

□ N-No □ Y-Yes □ NA-N/A	
1-Subject unable to comply 2-Subject refusal 3-Technical problem	<u> </u>
4-Clinic error 5-Laboratory error	
*Additional Options Listed Below	\blacksquare

Web Version: 1.0; 1.00; 08Dec20

If Other, specify:(LABBNOSP)

Chemistry

	Result	Expected Range
Creatinine	(LABCRRES) (x.x) mg/dl	0.3-1.7 mg/dl
Aspartate Aminotransferase (AST)	(LABASRES) (XX) u/L	2-40 u/L
Alanine Aminotransferase (ALT)	(LABALRES) (xx) u/L	3-30 u/L
Bilirubin (direct)	(LABBDRES) (x.x) mg/dl	0.0-0.4 mg/dl
Bilirubin (total)	(LABBTRES) (x.x) mg/dl	0.3-1.2 mg/dl

Infectious Disease Marker Testing

HIV 1 antigen	(LABHIV1A) 0-Negative 1-Positive
HIV 2 antigen	(LABHIV2A) 0-Negative 1-Positive
HBc core antigen	(LABHBC) 0-Negative 1-Positive
HBV surface antigen	(LABHBRES) 0-Negative 1-Positive
HCV surface antibody	(LABHCRES) 0-Negative 1-Positive
HTLV I	(LABHTLV1) 0-Negative 1-Positive
HTLV II	(LABHTLV2) 0-Negative 1-Positive
Chagas	(LABCHAGA) 0-Negative 1-Positive

Day -7 Visit Assessments

Day -7 collection date:(LABM7DT)

Were Day -7 assessments performed?(LAB7ASYN)

If No, reason not done:(LABM7NO)

If Other, specify:(LAB7NOSP)
Hemoglobin Electrophoresis

N-No Y-Yes NA-N/A

1-Subject unable to comply
2-Subject refusal
3-Technical problem
4-Clinic error
5-Laboratory error
*Additional Options Listed Below

	Result	Expected R	Range
Total Hemoglobin	(LABHGTOT) (xx) g/d	L 6-16 g/dL	
Hemoglobin A1 (HbA1)	(LABHGA1) (xx.x) %	6 95-97.9%	
Hemoglobin A2 (HbA2)	(LABHGA2) (x.x) %	2-3.5%	
Hemoglobin F (HbF)	(LABHGF) (x.x) %	0-2.1%	
Hemoglobin C (HbC)	(LABHGC) (xx) %	0-95%	
Hemoglobin S (HbS)	(LABHGS) (xx) %	0-95%	
Chemistry			
	Result		Expected Range
Lactic acid dehydrogenase	e (LDH) (LABLDH)	xxxx) U/L	100-1000 U/L
Ferritin	(LABFTL)	(xxxxx) ng/mL	10-10,000 ng/mL
Pregnancy Test Was a pregnancy test perfo	ormed?(LABPRGYN)		N-No Y-Yes NA-N/A
If Yes, specimen type:(LA	ABPGSPC)		U-Urine S-Serum
Specimen collection date	:(LABPRGDT)		(ddMMMyyyy)
Result:(LABPGRES)			0-Negative 1-Positive
Day -1 Visit Assessments	MADT)		
Day -1 collection date:(LAB			(ddMMMyyyy)
Were Day -1 assessments	•		N-No Y-Yes NA-N/A
If No, reason not done:(L	ABM INU)		1-Subject unable to comply
			2-Subject refusal
			3-Technical problem
			4-Clinic error
			5-Laboratory error *Additional Options Listed Below
If Other, specify:(LAB1	NOSP)		
Blood Grouping			
ABO(LABABO)			
Rh(LABRH)			N (Negative) P-+ (Positive)
• •	asma Reagin (RPR)(LABRPR)		□ N-Negative □ R-Reactive
RBC Antibody screening(LA	ABRBC)		☐ N-Negative ☐ P-Positive
Day 0 Visit Assessments Day 0 collection date:(LABI	D0DT)		(ddMMMyyyy)
Were Day 0 assessments	•		
If No, reason not done:(L	•		N-No Y-Yes NA-N/A
	/		1-Subject unable to comply
			2-Subject refusal
			3-Technical problem
			4-Clinic error 5-Laboratory error
			*Additional Options Listed Below
If Other, specify:(LAB0	NOSP)		
PRE-Collection			

CBC/Differential	Result		Expected Range	
Hematocrit	(LABHEMA1)	(xx) %	20-51%	
Reticulocytes	(LABRETC1)	(xx) %	0-30%	
Platelets	(LABPLAT1)	(xxx) x10 ³ /microliter	100-750 x10 ³ /microliter	
WBC	(LABWBC1)	(xx.x) x10 ³ /microliter	2.0-20.0 x10 ³ /microliter	
Neutrophils (Abs)	(LABNEU1)	(xx) x10 ³ /microliter	1-10 x10 ³ /microliter	
Lymphocytes (Abs)	(LABLYMP1)	(x) x10 ³ /microliter	1-5 x10 ³ /microliter	
Basophils (Abs)	(LABBASO1)	(x) x10 ³ /microliter	0-2 x10 ³ /microliter	
Eosinophils (Abs)	(LABEOSI1)	(x) x10 ³ /microliter	0-6 x10 ³ /microliter	
Monocyte (Abs)	(LABMONO1)	(xx) x10 ³ /microliter	0-20 x10 ³ /microliter	
Peripheral CD34+ count	(LABCD341)	(xxx) cells/microliter	0-200 cells/microliter	
Start of Collection				
CBC/Differential		Result	Expected Range	
Hematocrit	(LABHEMA2)	(xx) %	20-51%	
Reticulocytes	(LABRETC2)	(xx) %	0-30%	
	-		-	

CBC/Differential	Result	Expected Range
Hematocrit	(LABHEMA2) (XX) %	20-51%
Reticulocytes	(LABRETC2) (xx) %	0-30%
Platelets	(LABPLAT2) (xxx) x10 ³ /microliter	100-750 x10 ³ /microliter
WBC	(LABWBC2) (xx.x) x10 ³ /microliter	2.0-20.0 x10 ³ /microliter
Neutrophils (Abs)	(LABNEU2) (xx) x10 ³ /microliter	1-10 x10 ³ /microliter
Lymphocytes (Abs)	(LABLYMP2) (x) x10 ³ /microliter	1-5 x10 ³ /microliter
Basophils (Abs)	(LABBASO2) (x) x10 ³ /microliter	0-2 x10 ³ /microliter
Eosinophils (Abs)	(LABEOSI2) (x) x10 ³ /microliter	0-6 x10 ³ /microliter
Monocyte (Abs)	(LABMONO2) (xx) x10 ³ /microliter	0-20 x10 ³ /microliter
Peripheral CD34+ count	(LABCD342) (xxx) cells/microliter	0-200 cells/microliter

Additional Selection Options for LAB

If No, reason not done: 6-Investigator decision 99-Other



\$SITENAME - (\$SITECODE)

Lymphocytes (Abs) (NEGLYM)

(NEGBASO)

(NEGEOS)

(NEGMONO)

Basophils (Abs)

Eosinophils (Abs)

Monocyte (Abs)

▲ \$USERNAME

CD34 Negative Selection (NEG)

1-5 x10³/microliter

0-2 x10³/microliter

0-6 x10³/microliter 0-20 x10³/microliter Web Version: 1.0; 1.01; 08Dec20

Segment (PROTSEG):A Visit Number (VISNO):

Visit Date:(NEGVISDT)		(ddMMMyyyy)	
CD34 Negative Selection			
Name of sample proces	ssor:(NEGPROC)		(First Last)
Total number of cells pro	ocessed:(NEGTOTCL)	(xxx) x 10 ⁶ cell/mL	
% of CD34 negative cel	Is in collection:(NEGCD34)	(xx) %	
Are the CD34 negative (NEGFACSA)	selection FACS plots available for upload to eClinica	I? N-No Y-Yes	
If Yes, were the plots	uploaded?	N-No Y-Yes	
Select [Browse] and o	se the [Upload file] button at the bottom of the screen choose the file you intend to upload. Include a short (ex.: ParticipantID_NegSelect). Select [Upload].	L.	
Hematology	Result	Expected Range	
Platelets	(NEGPLT) (xxx) x10 ³ /microliter	100-750 x10 ³ /microliter	
WBC	(NEGWBC) (xx.x) x10 ³ /microliter	2.0-20.0 x10 ³ /microliter	
Neutrophils (Abs)	(NEGANC) (xx) x10 ³ /microliter	1-10 x10 ³ /microliter	

(xx) x10³/microliter

(xx) x10³/microliter (xx) x10³/microliter

(xx) x103/microliter



\$SITENAME - (\$SITECODE)

▲ \$USERNAME

CD34 Positive Selection (POS)

Web Version: 1.0; 1.01; 08Dec20

Segment (PROTSEG):A Visit Number (VISNO):

Visit Date:(POSVISDT)	(ddMMMyyyy)
CD34 Positive Selection Name of sample processor:(POSPROC)	(5)
Total number of cells processed:(POSTOTCL)	(First Last) (First Last)
% of CD34 positive cells in collection:(POSCD34)	(xx) %
Are the CD34 positive selection FACS plots available for upload to eClinical? (POSFACSA)	N-No Y-Yes
If Yes, were the plots uploaded?	□ N-No □ Y-Yes
To upload the plot, use the [Upload file] button at the bottom of the screen. Select [Browse] and choose the file you intend to upload. Include a short description of the file (ex.: ParticipantID_PosSelect). Select [Upload]. (POSFACSU)	

Hematology	Re	esult	Expected Range
Platelets	(POSPLT)	(xxx) x10 ³ /microliter	100-750 x10 ³ /microliter
WBC	(POSWBC)	(xx.x) x10 ³ /microliter	2.0-20.0 x10 ³ /microliter
Neutrophils (Abs)	(POSANC)	(xx) x10 ³ /microliter	1-10 x10 ³ /microliter
Lymphocytes (Abs)	(POSLYM)	(xx) x10 ³ /microliter	1-5 x10 ³ /microliter
Basophils (Abs)	(POSBASO)	(xx) x10 ³ /microliter	0-2 x10 ³ /microliter
Eosinophils (Abs)	(POSEOS)	(xx) x10 ³ /microliter	0-6 x10 ³ /microliter
Monocyte (Abs)	(POSMONO)	(xx) x10 ³ /microliter	0-20 x10 ³ /microliter



\$SITENAME - (\$SITECODE)

▲ \$USERNAME

Pre-CD34 Selection (PRE)

Web Version: 1.0; 1.01; 08Dec20

Segment (PROTSEG):A Visit Number (VISNO):

Visit Date:(PREVISDT)	(ddMMMyyyy)
Pre-CD34 Selection Name of sample processor:(PREPROC)	(First Last)
Total blood volume processed:(PRETOTBV)	(xxx) mL
Total number of cells collected:(PRETOTCL)	(xxxx) x 10 ⁶ cell/mL
Final volume of cell suspension:(PRECLSUS)	(xxx) mL
% of CD34 cells in cells collected:(PRECD34)	(xx) %
Are the Pre-CD34 selection FACS plots available for upload to eClinical? (PREFACSA)	N-No Y-Yes
If Yes, were the plots uploaded?	N-No Y-Yes
To contract the color was the filled and filed between at the between of the contract	

To upload the plot, use the [Upload file] button at the bottom of the screen. Select [Browse] and choose the file you intend to upload. Include a short description of the file (ex.: ParticipantID_PreSelect). Select [Upload]. (PREFACSU)

Hematology	F	Result	Expected Range
Hematocrit	(PREHCT)	(xx) %	20-51%
Platelets	(PREPLT)	(xxx) x10 ³ /microliter	100-750 x10 ³ /microliter
WBC	(PREWBC)	(xx.x) x10 ³ /microliter	2.0-20.0 x10 ³ /microliter
Neutrophils (Abs)	(PREANC)	(xx) x10 ³ /microliter	1-10 x10 ³ /microliter
Lymphocytes (Abs)	(PRELYM)	(xx) x10 ³ /microliter	1-5 x10 ³ /microliter
Basophils (Abs)	(PREBASO)	(xx) x10 ³ /microliter	0-2 x10 ³ /microliter
Eosinophils (Abs)	(PREEOS)	(xx) x10 ³ /microliter	0-6 x10 ³ /microliter
Monocyte (Abs)	(PREMONO)	(xx) x10 ³ /microliter	0-20 x10 ³ /microliter



\$SITENAME - (\$SITECODE)

▲ \$USERNAME

Sickle Collection Intake (SCI)

Web Version: 1.0; 1.00; 08Dec20

Segment (PROTSEG):A Visit Number (VISNO):

1.Visit date:(SCIVISDT)	(ddMMMyyyy)
Visit-Specific Information	
2.Was the informed consent document signed and dated prior to any study procedures being performed?(SCIICSD) Participant-Specific Information	■ N-No ■ Y-Yes
3. Sickle Cell Disease Genotype: (SCISCDG)	□ 1-HbSS □ 2-HbSC □ 3-HbSβ ⁰⁻ thalassemia □ 4-HbSβ ⁺⁻ thalassemia □ 5-HbSD
4. Has the participant received chronic blood transfusions?(SCIBLTFX)	N-No Y-Yes
a.lf Yes, how many transfusions have been received in the past 12 months? (SCITFNUM)	(xx) transfusions
5.How many vaso-occlusive events has the participant experienced in the past 12 months? (SCIVONUM)	(xx) events
 a.Number of these vaso-occlusive events which required narcotics or hospital admissions.(SCIVONHA) 	(xx) events
6.Has the participant had a splenectomy?(SCISPLEN)	□ N-No □ Y-Yes
a.lf Yes, how was the procedure performed?(SCISPPER)	☐ 1-Laparoscopically ☐ 2-Surgically
7.Has the participant experienced any Central Nervous System (CNS) events? (SCICNSEV)	N-No Y-Yes
a.lf Yes, indicate all CNS event(s) which have occurred:(SCISTROK)	□ 1-Stroke (SCITIA)□ 1-Transient ischemic attack (SCISEIZR)□ 1-Seizures
4 15 0 11 15 16 16 16 16 16 16 16 16 16 16 16 16 16	(SCICNSOT) 1-Other
1.If Other, specify:(SCICNSSP)	(SCICNSOT) 1-Other
1.If Other, specify:(SCICNSSP) 8.Has the participant ever taken hydroxyurea (HU)?(SCIHU)	(SCICNSOT) 1-Other N-No Y-Yes
8. Has the participant ever taken hydroxyurea (HU)?(SCIHU)	N-No Y-Yes N-No Y-Yes
8.Has the participant ever taken hydroxyurea (HU)?(SCIHU) a.lf Yes, did they respond to taking HU?(SCIHURES)	N-No Y-Yes N-No Y-Yes
8.Has the participant ever taken hydroxyurea (HU)?(SCIHU) a.If Yes, did they respond to taking HU?(SCIHURES) b.If Yes, are they presently taking HU?(SCIHUPR)	N-No
8. Has the participant ever taken hydroxyurea (HU)?(SCIHU) a. If Yes, did they respond to taking HU?(SCIHURES) b. If Yes, are they presently taking HU?(SCIHUPR) 9. What is the highest the participant's Hemoglobin F (HgF) has been?(SCIHGF)	N-No Y-Yes N-No Y-Yes N-No Y-Yes (xx) % (SCIHGUNK) 1-Unknown
8. Has the participant ever taken hydroxyurea (HU)?(SCIHU) a. If Yes, did they respond to taking HU?(SCIHURES) b. If Yes, are they presently taking HU?(SCIHUPR) 9. What is the highest the participant's Hemoglobin F (HgF) has been?(SCIHGF) 10. Has the participant undergone a Red Cell Exchange in the past year?(SCIRCEX)	N-No Y-Yes N-No Y-Yes N-No Y-Yes (xx) % (SCIHGUNK) 1-Unknown N-No Y-Yes
8. Has the participant ever taken hydroxyurea (HU)?(SCIHU) a. If Yes, did they respond to taking HU?(SCIHURES) b. If Yes, are they presently taking HU?(SCIHUPR) 9. What is the highest the participant's Hemoglobin F (HgF) has been?(SCIHGF) 10. Has the participant undergone a Red Cell Exchange in the past year?(SCIRCEX) a. If Yes, when?(SCIRCXDT)	N-No
8. Has the participant ever taken hydroxyurea (HU)?(SCIHU) a. If Yes, did they respond to taking HU?(SCIHURES) b. If Yes, are they presently taking HU?(SCIHUPR) 9. What is the highest the participant's Hemoglobin F (HgF) has been?(SCIHGF) 10. Has the participant undergone a Red Cell Exchange in the past year?(SCIRCEX) a. If Yes, when?(SCIRCXDT) Visit-Specific Screening Information 11. Was blood drawn for screening hematology labs?(SCIBLDHE)	N-No Y-Yes N-No Y-Yes N-No Y-Yes (xx) % (SCIHGUNK) 1-Unknown N-No Y-Yes (ddMMMyyyy) N-No Y-Yes
8. Has the participant ever taken hydroxyurea (HU)?(SCIHU) a. If Yes, did they respond to taking HU?(SCIHURES) b. If Yes, are they presently taking HU?(SCIHUPR) 9. What is the highest the participant's Hemoglobin F (HgF) has been?(SCIHGF) 10. Has the participant undergone a Red Cell Exchange in the past year?(SCIRCEX) a. If Yes, when?(SCIRCXDT) Visit-Specific Screening Information 11. Was blood drawn for screening hematology labs?(SCIBLDHE) 12. Was blood drawn for screening serology tests (HIV, HBV, and HCV)?(SCIBLDSE) 13. Female participants only: Was blood or urine collected for pregnancy testing? (N/A if female of nonchildbearing potential)(SCIPRTST) Medications/Protocol Deviations	N-No Y-Yes N-No Y-Yes N-No Y-Yes (xx) % (SCIHGUNK) 1-Unknown N-No Y-Yes (ddMMMyyyy)
8. Has the participant ever taken hydroxyurea (HU)?(SCIHU) a. If Yes, did they respond to taking HU?(SCIHURES) b. If Yes, are they presently taking HU?(SCIHUPR) 9. What is the highest the participant's Hemoglobin F (HgF) has been?(SCIHGF) 10. Has the participant undergone a Red Cell Exchange in the past year?(SCIRCEX) a. If Yes, when?(SCIRCXDT) Visit-Specific Screening Information 11. Was blood drawn for screening hematology labs?(SCIBLDHE) 12. Was blood drawn for screening serology tests (HIV, HBV, and HCV)?(SCIBLDSE) 13. Female participants only: Was blood or urine collected for pregnancy testing? (N/A if female of nonchildbearing potential)(SCIPRTST)	N-No